Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Senti Biosciences (Nasdaq: SNTI) announced that CEO Timothy Lu will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, 3:10–3:40 PM ET. The presentation will cover the Gene Circuit platform, pipeline progress, and partnership opportunities. Live audio and video webcasts will be available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – SNTI
On the day this news was published, SNTI gained 7.08%, reflecting a notable positive market reaction. This price movement added approximately $2M to the company's valuation, bringing the market cap to $25M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SNTI was up 0.99% while momentum peers such as XLO were moving down. Among close biotech peers, moves were mixed with both gains and losses, supporting a stock-specific rather than sector-driven reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 20 | Conference presentation | Positive | +0.1% | Participation in Cell & Gene Live event showcasing Gene Circuit platform. |
| Feb 11 | Clinical milestone | Positive | -1.9% | Completion of Phase 1 SENTI‑202 enrollment with favorable ASH 2025 data. |
| Feb 03 | Conference selection | Positive | -3.0% | Selection for on‑stage presentation at Healthcare Conference Taipei 2026. |
| Jan 14 | Investor presentation | Positive | +3.8% | Virtual CEO Connect segment on AML data and RMAT designation. |
| Jan 09 | Panel participation | Positive | +2.8% | CEO panel at Biotech Showcase 2026 on advances in cell and gene therapies. |
Recent company-communication and event headlines usually saw modestly positive price alignment, with one notable divergence on strong clinical progress.
Over the last few months, Senti Biosciences highlighted its Gene Circuit platform and SENTI‑202 program through multiple conferences and investor events. These included panel and on‑stage presentations in January–February 2026 and a virtual Cell & Gene Live appearance on February 19, 2026. A key milestone was completion of SENTI‑202 Phase 1 enrollment with favorable ASH 2025 data and RMAT designation. Today’s TD Cowen conference appearance continues this pattern of visibility-focused news rather than incremental clinical or financial disclosures.
Market Pulse Summary
The stock moved +7.1% in the session following this news. A strong positive reaction aligns with Senti’s pattern of modest gains on visibility events, such as prior conference and investor presentations. However, the company’s filings highlight ongoing net losses of $18.1M in Q3 2025 and cash of $12.2M, underscoring financing risk. Historically, even clearly positive clinical milestones did not always sustain upside, suggesting that enthusiasm around conference spotlights alone could fade without further de‑risking.
Key Terms
gene circuit technical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET.
Live audio of the webcast will be available on the Events page of the Investors section of the Company’s website (sentibio.com).
Interested parties may access the live video webcast here.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
When and where will Senti Biosciences (SNTI) present at the TD Cowen conference?
How can investors access the SNTI webcast for the March 2, 2026 presentation?
What topics will Timothy Lu cover in the Senti Biosciences (SNTI) presentation?
Will Senti Biosciences (SNTI) discuss partnership opportunities at the TD Cowen 2026 session?
Who is presenting for Senti Biosciences (SNTI) at the TD Cowen conference and what is his role?
